A-New Bio Inc. was selected for work supporting innovation in poultry biotechnology and avian influenza resistance.
Enabling Next-Generation Stem Cell Technologies
ANB develops proprietary culture technologies for stem cells and progenitor cells, supporting applications in research, regenerative medicine, cell therapy, and agricultural biotechnology. By improving the ability to maintain and expand functional cell populations in vitro, ANB aims to provide enabling technologies that support scientific discovery, therapeutic development, and future cell manufacturing platforms.
Platforms
Technology Platforms
ANB is developing proprietary culture technologies for blood stem cell and avian stem cell platforms. The company's work focuses on maintaining cellular quality, functional potential, and consistency across stem cell and progenitor cell systems.
Blood Stem Cell Technologies
Culture systems designed to support the maintenance and expansion of blood-forming stem and progenitor cells for future research and therapeutic applications.
Avian Stem Cell Technologies
Stem cell platforms supporting avian genetic engineering, agricultural biotechnology, disease-resistance research, and next-generation avian research models.
Applications
Applications & Partnerships
ANB is developing proprietary culture technologies that support the development and manufacturing of advanced cellular products.
Research ReagentsCell Therapy DevelopmentClinical-Grade Cellular Starting MaterialsStrategic PartnershipsLicensing OpportunitiesAgricultural Biotechnology
News
News & Updates
ANB continues to advance avian embryonic stem cell technologies for genetic engineering and agricultural biotechnology applications.
ANB's scientific foundation includes peer-reviewed work supporting the derivation of embryonic stem cells across avian species.
Leadership
Founding Leadership
Daping XiaCo-Founder & Chief Executive Officer
Leads corporate strategy, business development, financing strategy, partnerships, and company operations.
Qilong Ying, Ph.D.Co-Founder & Chief Scientific Officer
Leads scientific vision and platform innovation across stem cell culture technologies and translational research programs.
Daniel McKim, Ph.D.Founding Executive & Chief Operating Officer
Leads operational execution, translational development, program planning, and research-to-product advancement.
Zheng Guo, Ph.D.Founding Scientist
Contributes to platform development, experimental execution, and stem cell technology innovation.
Contact
Contact ANB
ANB welcomes conversations with potential research collaborators, strategic partners, biotechnology companies, investors, and translational advisors.
PartnershipsResearch collaboration, platform evaluation, and strategic development discussions.
Business DevelopmentLicensing, sponsored research, commercial partnerships, and investor inquiries.